Patient Demographics and Baseline Disease Characteristics
| . | SCF + Filgrastim . | Filgrastim . | Total . |
|---|---|---|---|
| n | 55 | 47 | 102 |
| Sex (%) | |||
| Male | 36 (65) | 24 (51) | 60 (59) |
| Female | 19 (35) | 23 (49) | 42 (41) |
| Age (yrs) | |||
| Median | 60 | 59 | 59 |
| Range | 38-66 | 37-65 | 37-66 |
| Stage (DS) at diagnosis (%) | |||
| I | 1 (2) | 3 (6) | 4 (4) |
| II | 10 (18) | 10 (21) | 20 (20) |
| IIIA | 42 (76) | 33 (70) | 75 (74) |
| IIIB | 2 (4) | 1 (2) | 3 (3) |
| ECOG score (%) | |||
| 0 | 19 (35) | 21 (45) | 40 (39) |
| 1 | 32 (58) | 23 (49) | 55 (54) |
| 2 | 4 (7) | 3 (6) | 7 (7) |
| Prior cycles of chemotherapy | |||
| Median | 3 | 3 | 3 |
| Range | 1-38 | 3-19 | 1-38 |
| No. of patients receiving prior radiotherapy (%) | 12 (22) | 13 (28) | 25 (25) |
| . | SCF + Filgrastim . | Filgrastim . | Total . |
|---|---|---|---|
| n | 55 | 47 | 102 |
| Sex (%) | |||
| Male | 36 (65) | 24 (51) | 60 (59) |
| Female | 19 (35) | 23 (49) | 42 (41) |
| Age (yrs) | |||
| Median | 60 | 59 | 59 |
| Range | 38-66 | 37-65 | 37-66 |
| Stage (DS) at diagnosis (%) | |||
| I | 1 (2) | 3 (6) | 4 (4) |
| II | 10 (18) | 10 (21) | 20 (20) |
| IIIA | 42 (76) | 33 (70) | 75 (74) |
| IIIB | 2 (4) | 1 (2) | 3 (3) |
| ECOG score (%) | |||
| 0 | 19 (35) | 21 (45) | 40 (39) |
| 1 | 32 (58) | 23 (49) | 55 (54) |
| 2 | 4 (7) | 3 (6) | 7 (7) |
| Prior cycles of chemotherapy | |||
| Median | 3 | 3 | 3 |
| Range | 1-38 | 3-19 | 1-38 |
| No. of patients receiving prior radiotherapy (%) | 12 (22) | 13 (28) | 25 (25) |